Civica by the Numbers
Civica to Manufacture and Distribute Affordable Insulin
Through a transformative collaboration between Civica and dedicated partners representing nearly every corner of the diabetes ecosystem, Americans with diabetes will have access to more affordable insulins. This transparent, cost-plus model will drastically reduce out-of-pocket costs for insulin.
“Diabetes is arguably America’s most expensive chronic condition, and it is heartbreaking that millions of people are rationing their care and putting their lives at risk because they can no longer afford insulin. Through mission-driven partnerships, we are choosing to create a new market reality where no one is forced to ration essential diabetes medications.”
Civica Hill Briefing: Civica to Manufacture and Distribute Affordable Insulin
Insulin Has Been Around for 100 Years, So Why Is It Still So Expensive?
“Our objective is to generate a societal return, improving affordability and alleviating human suffering while demonstrating that market solutions exist that can help moderate the effects of capitalism unrestrained by notions of right and wrong—models that put the needs of the patient first and always.”
A Radical Treatment for Insulin Pricing
“If Civica does deliver on its plan, it will disrupt the status quo for an important set of drugs and establish a path for reducing prices for other biologic medications whose market exclusivity periods have passed.”
Diabetes Connections: We Can Do It – Civica Rx and Non-Profit Insulin
Hear from Civica Chief Operating Officer Ned McCoy on Civica’s plans to manufacture and sell three types of insulin for one low-cost to patients who require it – regardless of insurance coverage.
How Affordable Insulin Happened
Listen to Juicebox Podcast: Civica CEO and President Martin VanTrieste speaks with Scott Benner, the writer of the popular diabetes parenting blog, Arden’s Day, and the award-winning parenting memoir, “Life Is Short, Laundry Is Eternal: Confessions of a Stay-at-Home Dad.” Their conversation about Civica’s development and Martin’s role brings listeners the story about Civica’s Insulin Initiative, through which Civica will manufacture and deliver three types of insulin to consumers for one low price beginning in 2024.
Civica Announces Leadership Transition
Effective June 1, Ned McCoy, formerly Civica’s Chief Operating Officer, succeeds Martin VanTrieste as Civica’s President and Chief Executive Officer. Martin remains an advisor to the Company and continues serving on Civica’s Board of Directors. As part of this transition, Ned also joins the Civica Board of Directors.
“I look forward to continuing to work with our talented team and furthering our culture of innovation, excellence and dedication to improving patient lives with a new model for generic hospital and prescription medicines.”
Profil Selected as Clinical Trial Partner for Affordable Insulin Initiative
Civica chose Profil as clinical trial partner to support the development of its affordable insulin biosimilars. Profil is the leading clinical research organization for studies related to diabetes and obesity.
Civica’s Sister Organization CivicaScript™ Welcomes New Members
CivicaScript™, Civica’s sister organization focused on lower prices at the pharmacy counter, welcomes new members EmsanaRx and Health Care Service Corporation.
Civica Joins the End Drug Shortages Alliance
Shortages of generic drugs critical to the lifesaving work of hospitals in the U.S. have become far too commonplace. Working to solve this issue, Civica has joined the End Drug Shortages Alliance, a new coalition of diverse stakeholders to address drug shortages in the United States.
And So It Begins – Equipment Arrives at Civica Manufacturing Plant
The equipment to fill vials of affordable insulin and essential medicines used for critical patient care in hospitals arrived in July at our Civica Rx manufacturing plant in Petersburg, Virginia. Watch it leaving Germany…
Thank you to groninger & co. gmbh, CRB and SKAN AG for their partnership in getting us to this milestone. We look forward to the day when this vial line will help us ensure quality medicines are available and affordable across the country.
Navitus Health Solutions Joins CivicaScript™
Navitus Health Solutions joins CivicaScript™ as a founding member. An industry-disrupting pharmacy benefit manager (PBM), Navitus is committed to bringing humanity to pharmacy benefits management through greater transparency and affordability.
Mayo Clinic Q&A Podcast: Combating Drug Shortages
Civica is mentioned as a solution.
“Civica’s insulin project will ensure that patients have the capability to manage their insulin by making it available and affordable to all who need it.”
CivicaScript™ Announces Launch of its First Product, Creating Significant Patient Savings
CivicaScript™ launches its first product: abiraterone acetate 250 mg tablets. Abiraterone is used together with steroid medication (prednisone) to treat prostate cancer that has spread to other parts of the body. The cost? As much as $3,000 per month less than the average cost for someone with Medicare Part D, the type of insurance people with prostate cancer are most likely to have.
Civica Turns 4!
Since our founding in 2018, we have secured supplies of essential generic medicines in hospitals across the country, used to treat nearly 40 million patients. With our partners and our talented, dedicated team, we celebrate this work and look ahead towards expanding our focus to deliver insulin and other critical medicines at affordable prices. We will always do what is in the best interest of patients.
Civica to Expand in Greater Richmond-Petersburg Region, Investing in New Testing Facility
Civica announces the construction of a 55,000 square foot facility to support the company’s Petersburg manufacturing operation through quality testing and development of new products. The project will create 51 new jobs.
“With this investment, Civica is building on its long-term commitment to patients – and to Virginia. This lab will support a skilled and highly trained workforce who will ensure Civica’s affordable insulin as well as other essential medicines meet the highest standards.”
Insulin Spending Caps Won’t Work. Here’s a Better Idea
With fairer rules in place, competitors should be able to force down the cost of insulin overall, to the benefit of consumers and taxpayers alike. Wherever possible, the goal should be removing impediments… and making it harder for the major manufacturers to maintain the status quo.
Insulin Costs Increased 600% Over the Last 20 Years. States Aim to Curb the Price
As leading manufacturers have increased prices of insulin by more than 600% over the last 20 years, many diabetes patients ration this lifesaving drug. So who’s helping?
“It’s more than a steel beam, it’s building the foundation for quality and affordable medication for millions of Americans.”
“This beam will cherish the names of Civica employees, partners, and visitors and be a daily reminder of just how many people we are helping to build a better tomorrow…
“Civica Rx has already partnered with nearly 60 health systems, over 1,500 hospitals, and produced more than 60 drugs. This facility, set in Virginia, will help produce insulin and lower the cost from $300 to $30 per vial. It will also produce numerous essential medicines hospitals rely on every day. On top of all that, the facility itself is helping to give more sustainable jobs and incomes for families in the area.”
Late-stage construction of the Civica Rx Petersburg VA manufacturing facility is well underway. And the facility now has a name.
With our hospital, philanthropy, government and manufacturing partners we are reducing drug shortages and avoiding predatory pricing. This facility will enable us to do more.
With CivicaScript and our partners in the diabetes, philanthropy, payor, health system, manufacturing and clinical trial communities, we are working to make this facility the future home of affordable insulin.
We are grateful for the warm welcome we are receiving from the greater Richmond and Petersburg communities and look forward to our continued collaboration.
Here’s the road to the future home of affordable insulin and essential sterile injectable medicines hospitals rely on every day.
The new address of our Civica Petersburg manufacturing facility is “One Civica Way”